Genprex Issues April 2020 Shareholder Letter
May 04 2020 - 8:17AM
Business Wire
- Company provides updates on recent regulatory, clinical,
operational, and business developments
- Fast Track Designation by FDA for Oncoprex™ in combination with
osimertinib in non-small cell lung cancer emphasized
- Exclusive license agreement with University of Pittsburgh for
diabetes gene therapy candidate highlighted
Genprex, Inc. (“Genprex” or the “Company”)
(Nasdaq: GNPX), a clinical-stage gene therapy company developing
potentially life-changing technologies for patients with cancer and
diabetes, announced that it has issued an April 2020 Shareholder
Letter. The letter highlights the Company’s progress with
Oncoprex™, its lead drug candidate with an initial targeted
indication for non-small cell lung cancer (NSCLC), its license
agreement for a diabetes gene therapy drug candidate, and other
operational and business achievements.
Recent Company Highlights Include:
- Receiving Fast Track Designation from the Food and Drug
Administration (FDA) for Oncoprex™ in combination with osimertinib
(AstraZeneca’s Tagrisso®) for the treatment of patients with
NSCLC
- Signing an exclusive license agreement with the University of
Pittsburgh for a preclinical diabetes gene therapy candidate that
may have the potential to cure Type 1 and Type 2 diabetes
- Obtaining encouraging preclinical data from research
collaborators and independent third parties with the TUSC2 gene,
the active agent in Oncoprex, in lung cancer and triple-negative
breast cancer
- Raising more than $26 million in gross proceeds from
institutional investors in three separate equity offerings
To read the letter in its entirety, view a digital copy of the
Company’s Shareholder Letter, which can be found on the Company’s
website here.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with
cancer and diabetes. Genprex’s technologies are designed to
administer disease-fighting genes to provide new treatment options
for large patient populations with cancer and diabetes who
currently have limited treatment options. Genprex works with
world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies
in order to provide novel treatment approaches. The Company’s lead
product candidate, Oncoprex™, is being evaluated as a treatment for
non-small cell lung cancer (NSCLC). Oncoprex has a multimodal
mechanism of action that has been shown to interrupt cell signaling
pathways that cause replication and proliferation of cancer cells;
re-establish pathways for apoptosis, or programmed cell death, in
cancer cells; and modulate the immune response against cancer
cells. Oncoprex has also been shown to block mechanisms that create
drug resistance. In January 2020, the U.S. Food and Drug
Administration granted Fast Track Designation for Oncoprex
immunogene therapy for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®). For more information, please
visit the Company’s web site at www.genprex.com or follow Genprex
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding our
current and potential commercial partnerships and intellectual
property licenses and regarding our financial resources. Risks that
contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of Oncoprex™, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including our gene therapy in
diabetes, advance into clinical trials; our ability to enter into
strategic partnerships and the success of those partnerships; the
timing and success of obtaining FDA approval of Oncoprex™ and our
other potential product candidates, including whether we receive
fast track or similar regulatory designations; whether patents will
ever be issued under patent applications that are the subject of
our license agreements; and the extent and duration of the current
and future economic and pandemic related challenges we may face.
These and other risks and uncertainties are described more fully
under the caption “Risk Factors” and elsewhere in our filings and
reports with the United States Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200504005095/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679), ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679), ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024